Schrodinger, Inc.
As of Oct 22, 2026, Schrodinger is in Stage 2, the uptrend phase, now in week 12 (since Jul 31, 2026). It closed at $22.60, 30.7% below its 52-week high and above its 200-day average, which is rising.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 16 in Health Information Services · #1 of 272 in Health Care
Is SDGR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SDGR among Health Information Services10th of 41 by relative strength
All 41 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | AMWL | Stage 2 · wk 25 | 97 | +7.4% |
| 2 | HNGE | Stage 2 · wk 20 | 96 | +19.1% |
| 3 | BTSG | Stage 3 · wk 8 | 94 | +9.1% |
| 4 | NRC | Stage 3 · wk 4 | 93 | −0.1% |
| 5 | SOPH | Stage 2 · wk 24 | 91 | −12.7% |
| 6 | HTFL | Stage 2 · wk 10 | 87 | +17.0% |
| 7 | HSTM | Stage 2 · wk 17 | 77 | +20.3% |
| 8 | OMCL | Stage 4 · wk 10 | 70 | +12.5% |
| …10 | SDGR | Stage 2 · wk 12 | 61 | −22.7% |
Schrodinger: quick answers
What stage is Schrodinger in?
As of Oct 22, 2026, Schrodinger (SDGR) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 31, 2026 and is in week 12. What the four stages mean
Is Schrodinger in an uptrend?
Yes. Schrodinger is in a Stage 2 uptrend. It trades 37.0% above its 200-day average, which is rising.
How far is Schrodinger from its 52-week high?
Schrodinger closed at $22.60 on Oct 22, 2026, 30.7% below its 52-week high of $32.60. Its 52-week low is $11.07.
How has Schrodinger performed over the past year?
As of Oct 22, 2026, Schrodinger is up 8.3% over the past year and up 25.7% so far in 2026.
Which sector and industry is Schrodinger in?
Schrodinger is in the Health Information Services industry, part of the Health Care sector.
About this companyHealth Care· Health Information Services
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.